Effectiveness of simplifying antiretroviral therapy to maintain viral suppression and improve bone and renal health: comparing simplified and non-simplified therapy
Preprint
Abstract
Objective: Nucleoside/nucleotide reverse transcriptase inhibitors, particularly tenofovir, can cause long-term side effects such as decreased bone mineral density and estimated glomerular filtration rate. A strategy to mitigate these effects is the simplification of antiretroviral therapy, which involves withdrawing one of the nucleoside/nucleotide reverse transcriptase inhibitors from the therapeutic scheme. While clinical trials and real-world studies have demonstrated that the simplified therapy maintains undetectable viral loads, its impact on bone mineral density and kidney function remains unclear owing to the lack of real-world evidence. Methods: This retrospective cohort study compared 152 patients who underwent antiretroviral therapy simplification (primarily due to osteopenia, osteoporosis, or decreased estimated glomerular filtration rate) with 306 patients who maintained triple therapy, between April 2013 and September 2022. The simplified regimens included lamivudine plus dolutegravir or ritonavir-boosted darunavir. The groups were analyzed based on their demographic characteristics using Student’s t-test in the case of symmetric data. Therapeutic success (undetectable viral load at the end of follow-up) was assessed using Kaplan Meier survival analysis . The estimated glomerular filtration rate variation before and after simplification was analyzed using the Mann-Whitney test . Pre-and post-simplification bone mineral density values were evaluated using the chi-square test for trends and assessed in the simplified therapy group. A significance level of 5% (α = 0.05) was adopted for all tests. Results: Simplified antiretroviral therapy was non-inferior to triple therapy in maintaining undetectable viral load. Patients receiving simplified regimens showed a positive variation in estimated glomerular filtration rate. A small subset of patients also exhibited improvements in bone mineral density after antiretroviral therapy simplification. Conclusions: These findings suggest that simplified therapy is as effective as triple therapy and has the additional benefit of reducing tenofovir-related adverse events.Keywords
This publication has 21 references indexed in Scilit:
- Update on treatment as prevention of HIV illness, death, and transmission: sub-Saharan Africa HIV financing and progress towards the 95–95–95 targetCurrent Opinion in HIV and AIDS, 2022
- Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate?Current HIV/AIDS Reports, 2020
- Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patientsInternational Journal of Infectious Diseases, 2019
- Osteoporosis-Related Fractures in HIV-Infected Patients Receiving Long-Term Tenofovir Disoproxil Fumarate: An Observational Cohort StudyDrug Safety, 2018
- Potential kidney toxicity from the antiviral drug tenofovirCurrent Opinion in Nephrology and Hypertension, 2018
- Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone healthAIDS, 2018
- Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1–Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational CohortAIDS Patient Care and STDs, 2017
- Changes in Kidney Function and in the Rate of Tubular Dysfunction After Tenofovir Withdrawal or Continuation in HIV-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2016
- Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patientsInternational Journal of Clinical Pharmacy, 2015
- Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agentsAIDS, 2012